Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 16 (3), 263-77

New Treatments for Chronic Hepatitis C

Affiliations
Review

New Treatments for Chronic Hepatitis C

Jae Young Jang et al. Korean J Hepatol.

Abstract

Treatments for chronic hepatitis C has evolved significantly in the past 15 years. The standard of care (SOC) is peginterferon alfa-2a/-2b with ribavirin for 48 weeks or 24 weeks in patients infected with HCV genotype 1 or 2/3, respectively. The treatment duration can be individualized based on the baseline viral load and the speed of the virologic response during treatment. However, current therapies are associated with side effects, complications, and poor patient tolerability. Therefore, there is an urgent need to identify better strategies for treating this disease. An improved sustained virologic response (SVR) can be achieved with new HCV-specific inhibitors against NS3/4A and NS5B polymerases. Recent trials have found SVR rates in patients with HCV genotype 1 infection of 61~68% and 67~75% for combining the SOC with the protease inhibitors telaprevir and boceprevir, respectively. Several new HCV-specific inhibitors such as protease inhibitors and nucleoside and non-nucleoside polymerase inhibitors as well as non-HCV-specific compounds with anti-HCV activity are currently in clinical evaluation. In this review we discuss these new treatments for chronic hepatitis C.

Figures

Figure 1
Figure 1
Schematic representation of the hepatitis C virus genome.
Figure 2
Figure 2
Life cycle of the hepatitis C virus.
Figure 3
Figure 3
Different target regions in the hepatitis C virus genome.

Similar articles

See all similar articles

Cited by 8 PubMed Central articles

See all "Cited by" articles

References

    1. Marcellin P, Boyer N. Transition of care between paediatric and adult gastroenterology. Chronic viral hepatitis. Best Pract Res Clin Gastroenterol. 2003;17:259–275. - PubMed
    1. Bartenschlager R, Lohmann V. Replication of the hepatitis C virus. Baillieres Best Pract Res Clin Gastroenterol. 2000;14:241–254. - PubMed
    1. Appel N, Schaller T, Penin F, Bartenschlager R. From structure to function: new insights into hepatitis C virus RNA replication. J Biol Chem. 2006;281:9833–9936. - PubMed
    1. Brass V, Moradpour D, Blum HE. Molecular virology of hepatitis C virus (HCV): 2006 update. Int J Med Sci. 2006;3:29–34. - PMC - PubMed
    1. Szabo G, Dolganiuc A. Hepatitis C and innate immunity: recent advances. Clin Liver Dis. 2008;12:675–692. x. - PMC - PubMed

MeSH terms

Feedback